Context: Parafibromin, encoded by HRPT2, is the first marker with significant benefit in the diagnosis of parathyroid carcinoma. However, because parafibromin is only involved in up to 70% of parathyroid carcinomas and loss of parafibromin immunoreactivity may not be observed in all cases of HRPT2 mutation, a complementary marker is needed.
are often absent in individual cases. Even with expert analysis by experienced endocrine pathologists in institutions performing large numbers of parathyroidectomies, the pathological diagnosis of parathyroid carcinoma is far from sensitive or specific (4, 5) .
Up to 50% of parathyroid carcinomas with biologically malignant behavior (i.e. recurrence and metastasis) may be considered benign using conventional clinicopathological criteria, and perhaps as few as 15% of all cases diagnosed as carcinoma prospectively on the basis of histological criteria will actually go on to behave in a malignant manner (reviewed in Ref. 1 ). It is impossible to determine whether the remaining 85% of histopathologically diagnosed carcinomas that do not go on to behave in a malignant manner represent malignancies cured by surgery or benign tumors mimicking carcinoma histologically. These cases may confound molecular analysis if not considered separately.
Recently, mutations in the HRPT2 tumor suppressor have been identified in sporadic parathyroid carcinoma and tumors arising in the autosomal dominant hyperparathyroidism-jaw tumor syndrome (HPT-JT), as well as more rarely in familial isolated hyperparathyroidism (6 -9) . Fifteen percent of members of HPT-JT kindreds will develop parathyroid carcinoma, whereas up to 80% will have benign parathyroid tumors that may be histologically atypical and clinically aggressive (reviewed in Refs. 1 and 10).
Up to 70% of apparently sporadic parathyroid carcinomas that behave in a biologically malignant manner carry an HRPT2 mutation (7, 8) . Between 20 and 30% of these carcinomas are associated with germline HRPT2 mutation indicating occult HPT-JT (8) . In some cases, "two hits" affecting HRPT2, either an additional mutation or loss of heterozygosity at the HRPT2 locus, have been reported (7, 8) . In contrast, HRPT2 mutations are extremely rare in unselected non-HPT-JT-related benign parathyroid disease occurring at an incidence of less than 1% (6, 7, 11) . Some reports suggest that cystic change is a feature of these rare benign tumors carrying HRPT2 mutations (6, 12) .
The gene expression profiles of all parathyroid tumors with an HRPT2 mutation, regardless of familial or sporadic origin or benign or malignant pathological classification, are remarkably similar (13) . Given this and the fact that HRPT2 mutation occurs so commonly in parathyroid carcinomas and is such a rare event in sporadic benign disease, we believe that even histologically benign parathyroid tumors harboring an HRPT2 mutation are best regarded as having at least some malignant potential (13) . HRPT2 mutation alone can therefore be considered a definitive criterion of malignancy.
Recently, HRPT2 mutation screening in patients suspected of HPT-JT and/or parathyroid carcinoma has largely been overtaken by immunohistochemistry for its protein product parafibromin as an initial screen, given the relative affordability and ease of translation to the diagnostic pathology laboratory. The combined results of several studies indicate that completely negative staining for parafibromin in the presence of positive internal controls (nonneoplastic stromal cells such as fibroblasts or lymphocytes that should stain positive for parafibromin) is highly specific for the diagnosis of parathyroid carcinoma or HPT-JT-associated adenoma (12, 14 -16) . In fact, only one of 307 (0.3%) unselected non-HPT-JT-associated benign parathyroids have been shown to be completely negative for parafibromin, and this one case was shown to harbor an HRPT2 mutation (14, 15, (17) (18) (19) . Despite this excellent specificity, negative staining for parafibromin has relatively poor sensitivity for the diagnosis of carcinoma. The same studies report sensitivities that may be as low as 23% (18) when histopathological criteria of malignancy are used as the gold standard but are generally much higher (average, ϳ70%) when biological evidence of malignant behavior is the gold standard (14, 15, 17, 19) . Regardless of which gold standard is used, it is clear that not all parathyroid carcinomas are HRPT2 mutated or parafibromin negative.
Focal or weak staining for parafibromin may be observed and is of uncertain significance. Studies have indicated that it occurs more frequently in parathyroid carcinomas, although it also occurs in a significant proportion of sporadic benign adenomas and cannot be considered unequivocal evidence of parathyroid carcinoma (12, 14, 15, 18) . Another difficulty with parafibromin immunohistochemistry is that it relies on negative rather than (15) . Therefore a marker of the parathyroid carcinoma/HPT-JT adenoma phenotype, which has a greater sensitivity but maintains the excellent specificity of parafibromin, used in conjunction with parafibromin may be of benefit in classifying individual cases, particularly if they are positive or weakly positive for parafibromin.
We previously reported gene expression profiling of parathyroid tumors and identified putative molecular classifiers for malignant and benign lesions (13) . Gene-Rave analysis (20) identified overexpression of ubiquitin carboxyl-terminal esterase L1 (UCHL1) as a statistically significant classifier for carcinoma and HPT-JT-related tumors. UCHL1 is a member of a gene family whose products hydrolyze small C-terminal adducts of ubiquitin to generate the ubiquitin monomer. Its protein product, protein gene product 9.5 (PGP9.5), is expressed in neuronal and neuroendocrine tissues (21) , as well as during embryonic development of the parathyroid glands in the rat (22) . Highly increased expression has been reported in a number of cancers, and the frequency of this expression associated with advanced staging (23) (24) (25) (26) (27) . Here we report the utility of immunohistochemical staining for PGP9.5 in conjunction with parafibromin for both sensitive and specific classification of malignant and benign parathyroid tumors.
Materials and Methods

Tissue samples
In total, 146 parathyroid tumor and nine normal tissue samples were analyzed. These were obtained from Royal North Shore Hospital, Sydney, Australia and Martin Luther University, Halle-Wittenberg, Germany, after approval from the Human Research Ethics committee of each institution. All available carcinoma and HPT-JT specimens were included in this study; however, samples for each benign subtype were randomly selected from a large archival pool. The parathyroid specimens for quantitative RT-PCR consisted of 10 sporadic adenomas, 10 secondary hyperplasias, seven carcinoma/HPT-JT specimens, and a pool of five normal parathyroid tissues collected from excess cell washings after routine parathyroid autotransplantation during thyroidectomy (13) . All parathyroid carcinoma specimens met the World Health Organization histopathological criteria for malignancy (3). The seven carcinoma or HPT-JT-related specimens consisted of four HPT-JT-related adenomas from two kindreds, each with two hits (a germline mutation in conjunction with either a somatic mutation or loss of heterozygosity) at the HRPT2 locus as previously described (7); two carcinomas with two or one somatic mutation(s); and one carcinoma that was not tested for HRPT2 mutations. All specimens were frozen in liquid nitrogen imme- diately after collection and stored at Ϫ80 C. RNA was extracted using TRI Reagent (Molecular Research Center Inc., Cincinnati, OH) and integrity checked by agarose gel electrophoresis. Specimens of good integrity (rRNA 28S/18S assessment) were purified using 7.5 M LiCl (Ambion Inc., Austin, TX). cDNA was prepared using the Superscript III First-Strand Synthesis System for RT-PCR (Invitrogen Corporation, Carlsbad, CA) and random hexamers. All procedures followed the manufacturers' recommendations. The parathyroid specimens for immunohistochemical staining consisted of formalin-fixed, paraffin-embedded blocks from 100 benign specimens (sporadic adenoma; primary, secondary, and tertiary hyperplasia; multiple endocrine neoplasia types 1 and 2A-related tumors; and normal tissue), 22 sporadic carcinomas, and five HPT-JT-related tumors as listed in Table 1 . Clinical findings for the parathyroid carcinomas and HPT-JT tumors are detailed in Table 2 . Carcinomas that in addition to meeting the histopathological criteria for malignancy, went on to behave in a biologically malignant manner, either recurring or metastasizing, were classed as unequivocal carcinomas (13 of 22) . Carcinomas that to date have not recurred or behaved in a malignant manner were classed as histopathological carcinomas (9 of 22). Three of the HPT-JT-related tumors and one sporadic carcinoma also underwent quantitative RT-PCR for UCHL1 (Table 2) . Parafibromin staining for the benign specimens (with the exception of one multiple endocrine neoplasia type 1 specimen) and 14 of the sporadic carcinomas and HPT-JT-related tumors has been previously published (15) ( Table 2) .
HRPT2 mutation testing was performed where possible by commercial sequencing of exons and exon/intron boundaries amplified from genomic DNA.
UCHL1 quantitation
Quantitative RT-PCR was performed using TaqMan Gene Expression Assays (UCHL1: Hs00188233_m1; Applied Biosystems, Foster City, CA) and TaqMan Universal PCR Master Mix, No AmpErase UNG (Applied Biosystems) on a Rotorgene 3000 instrument (Corbett Research, Mortlake, NSW, Australia). The endogenous control chosen for normalization was rRNA 18s (Hs99999901_s1), and the results were expressed as UCHL1: 18s. Triplicate assays were performed, and means, group means, and box plots were generated by SPSS version 12.0.1 (SPSS Inc., Chicago, IL). Differences between classes were assessed statistically using REST-XL version 2 software (28) . Samples that underwent both quantitative RT-PCR and immunohistochemical analyses are identified in Table 2 .
PGP9.5 and parafibromin immunohistochemistry
Immunohistochemistry for PGP9.5 was performed on formalinfixed, paraffin-embedded tissue using a rabbit polyclonal antibody (Z5116, Dako Australia Pty Ltd, Kingsgrove, NSW, Australia). A single representative block from each tumor was sectioned at 4 m onto positively charged slides (Superfrost plus; Menzel-Glaser, Braunschweig, Germany). Slides were then stained using the Vision Biosystems BondMax Autostainer (Vision Biosystems, Mount Waverley, Victoria, Australia), according to the manufacturer's protocol. Briefly this involved slides being dewaxed in Bond Dewax solution (AR9222, Vision Biosystems) and hydrated in Bond Wash solution (AR9590, Vision Biosystems). Antigen retrieval was performed at acidic pH using Epitope Retrieval 1 Solution (AR9961, Vision Biosystems) for 30 min at 100 C. Slides were then incubated with the primary antibody at a dilution of 1:400 for 30 min at room temperature. Antibody detection was performed using the biotin free Bond Polymer Defined Detection System (DS9713 Vision Biosystems) according to the manufacturer's protocol. Slides were then counterstained with hematoxylin. External positive and negative controls were run with each batch of slides. Tumors were scored by a single pathologist who was blinded as to other data. Tumors were described as positive if there was diffuse strong positive staining for PGP9.5 (arbitrarily defined as more than 50% of tumor cells being positive but usually more than 80%). All other patterns of staining were scored as negative.
Immunohistochemistry for parafibromin was performed and scored as previously described (15) , with the exception that the focal/weak pattern of staining category was not used. Tumors were scored as negative only if completely absent nuclear staining for parafibromin was found in the presence of an internal positive control, and all other patterns including focal or weak staining were considered positive.
Results
UCHL1 transcript levels are increased in parathyroid carcinomas and HPT-JT-related tumors compared with non-HPT-JT benign parathyroid tumors
Previously, analysis of expression microarray data identified increased expression of UCHL1 as a putative marker of malignancy in parathyroid tumors (29) . To confirm this increased expression of UCHL1 in sporadic carcinomas and HPT-JT-related tumors, we performed quantitative RT-PCR on three different subtypes of parathyroid tumors and a pool of normal tissue. The results of triplicate assays are shown in Fig. 1 . Individual specimen results are shown in Fig. 1A , and the combined results for each tumor class are shown in Fig. 1B . UCHL1 was highly expressed in the arcinoma/HPT-JT subgroup compared with normal (P Ͻ 0.05) and benign specimens (P Ͻ 0.001). Similar results were obtained using The shaded boxes contain 50% of the data, and the median is the black line inside the box. The whiskers are drawn so that the lower whisker is at the smallest value that is not lower than the first quartile minus 1.5 interquartile range (IQR), and the upper whisker is at the largest value that is not higher than the third quartile plus 1.5 IQR, where IQR is the first quartile minus the third quartile. Adenoma, Sporadic adenoma; Hyperplasia, secondary hyperplasia; Normal, pool of normal tissue; CARC/HPT-JT, sporadic carcinomas and HPT-JT-related tumors.
an alternative reference or endogenous control gene, signal sequence receptor ␥ (TaqMan probe Hs00606481_m1) that was chosen from previously published microarray data (13) because it demonstrated no tumor class bias, low variance, and low maximum absolute deviation (data not shown). These results confirm the findings from analysis of microarray data and suggest increased expression of UCHL1 as a marker of malignancy or malignant potential for parathyroid tumors.
Immunohistochemistry for PGP9.5 and parafibromin
Immunohistochemistry for parafibromin and PGP9.5 was performed on 100 benign specimens (including four normal parathyroids), five HPT-JT-related tumors, 13 unequivocal sporadic carcinomas, and nine histopathological sporadic carcinomas. The results for both proteins and for all specimens are summarized in Table 1 . Individual results for the sporadic carcinomas and HPT-JT-related tumors are detailed along with HRPT2 mutation status, where available, in Table 2 . Representative images of staining are shown in Fig. 2 . When positive, PGP9.5 showed both nuclear and cytoplasmic positivity in virtually all tumor cells. We did note that many benign parathyroid tumors and some normal parathyroids showed focal staining for PGP9.5 in approximately 5-10% of cells. As per our described criteria, this pattern was classified as negative.
PGP9.5 is a sensitive marker for parathyroid malignancy
Excluding carcinomas that to date have not demonstrated clinically malignant behavior (histopathological carcinomas), for the remaining specimens (benign, HPT-JT and unequivocal carcinomas, n ϭ 118), diffuse and strong (positive) staining for PGP9.5 had a sensitivity of 78% for malignancy and/or HRPT2 mutation and a specificity of 100% (95% confidence interval, 95-100%). Complete lack of nuclear parafibromin staining had a sensitivity of 67% and specificity of 100%. These results suggest that positive staining for PGP9.5 has utility as a marker for parathyroid malignancy, with a slightly superior sensitivity and similar high specificity to that of parafibromin.
Positive staining for PGP9.5 correlates with negative staining for parafibromin Loss of nuclear expression of parafibromin correlated well with positive staining for PGP9.5, and we found that all 14 parafibromin-negative cases were also positive for PGP9.5 (Table 1 ). In addition, PGP9.5 was positive in five cases that were positive for parafibromin (Tables 1 and 2 ), a significant increase in sensitivity for detection of parathyroid carcinoma (P ϭ 0.03, McNemar's one-tailed test). Three of these cases were histopathologically diagnosed carcinomas that had not yet behaved in a malignant manner. Intriguingly, one other case was a previously described HPT-JT adenoma known to harbor the missense HRPT2 mutation (L64P) with loss of the corresponding wild-type allele, but showed focal, positive staining for parafibromin (Fig. 2F) (15) . This result suggests that positive staining for PGP9.5 can be used as a marker of malignancy in tumors that express parafibromin but harbor a missense HRPT2 mutation. No sporadic or multiple endocrine neoplasia-related benign parathyroids were PGP9.5 positive. , ϫ200) . B, Benign sporadic adenoma showing negative staining for PGP9.5 and diffuse strong nuclear positivity for parafibromin (original magnification, ϫ400). C, Parathyroid carcinoma showing diffuse strong PGP9.5 staining and absent nuclear staining for parafibromin (original magnification, ϫ400). D, HPT-JT adenoma with the HRPT2 mutation c.1247delG showing diffuse PGP9.5 staining in the adenoma but absent staining in the nonneoplastic parathyroid. There is complete absence of staining for parafibromin in neoplastic cells with stromal cells and adjacent nonneoplastic tissue acting as positive internal controls (arrows) (original magnification, ϫ200). E, Histopathologically diagnosed parathyroid carcinoma showing positive staining for PGP9.5 and weak/focal staining for parafibromin (original magnification, ϫ200). F, HPT-JT adenoma with the missense HRPT2 mutation L64P and loss of the wild-type allele showing focal, positive parafibromin staining and positive staining for PGP9.5 (original magnification, ϫ200).
Predicting malignant or benign behavior of histological carcinomas
Using the above results as predictors for malignant or benign behavior, we next stratified the nine histopathological carcinomas, defined as histopathologically classified carcinomas that to date have not shown malignant behavior (Table 3 ). Taking either positive staining for PGP9.5 or negative staining for parafibromin as evidence of a malignant phenotype, 55% (5 of 9) would be classed as malignant and 45% (4 of 9) as benign. Seven of the patients from whom these specimens were collected have been followed for up to 18 months ( Table 2 ). Given that parathyroid carcinoma is often an indolent neoplasm with metastasis or recurrence not evident for many years or decades, only ongoing follow-up will determine whether histopathologically malignant parathyroid tumors that are PGP9.5 positive are more likely to behave in a malignant manner than similar tumors that are PGP9.5 negative.
Discussion
Our study provides strong evidence that PGP9.5 positivity complements, and in some cases might be superior to, parafibromin negativity as a marker of malignancy and the HPT-JT adenoma phenotype in parathyroid tumors. We demonstrated that diffuse positive staining for PGP9.5 is highly correlated with completely negative parafibromin staining and with biologically malignant behavior of parathyroid tumors. Indeed, diffuse positive staining for PGP9.5 was found in all parafibromin negative tumors. These immunohistochemical results were supported by quantitative RT-PCR analysis that showed high expression of UCHL1, specifically in the carcinoma group.
Diffuse positive staining for PGP9.5 also occurred in the parafibromin-positive tumor with the HRPT2 mutation L64P. Because missense mutations represent up to 10% of all reported HRPT2 mutations (reviewed in Ref. 1) , the possibility of positive staining for tumors harboring these mutations, as seen for L64P, reduces the sensitivity of parafibromin staining for the diagnosis of parathyroid carcinoma or malignant potential. Furthermore, up to 30% of parathyroid tumors with biologically malignant behavior may not harbor an HRPT2 mutation and so may not be identified as malignant on presentation if parafibromin is the only additional criterion used to aid diagnosis. Of the five parafibromin-positive unequivocal carcinomas (with malignant behavior), one was positive for PGP9.5, suggesting that PGP9.5 has a slightly higher sensitivity than parafibromin not only for detection of an HRPT2 mutation, but also for malignancy. This increase in sensitivity was not associated with a decrease in specificity because none of 100 unselected benign parathyroids were positive for PGP9.5, and the only three additional tumors that were both PGP9.5 and parafibromin positive met the World Health Organization criteria for parathyroid carcinoma.
PGP9.5 overexpression is associated with increased proliferation (30 -32) but, at least in embryonic fibroblasts from parafibromin knockout mice, does not seem to be a direct consequence of loss of parafibromin per se (33) . Intriguingly, both loss of parafibromin and overexpression of PGP9.5 are reported in aggressive breast cancer, although whether these occur together as in parathyroid carcinoma remains to be determined (34, 35) . Overexpression of PGP9.5 is also associated with aggressive behavior in lung cancer, pancreatic cancer, gall bladder cancer, medullary thyroid cancer, renal cell carcinoma metastases, and myeloma (23, 25, 26, 34, 36 -38) . In some cancers, overexpression is consistent with changed methylation status of the UCHL1 promoter (38) . This does not appear to be the case in parathyroid carcinoma (data not shown) or lung cancer where there is no evidence of hypermethylation in normal or tumor tissue (39 From our results, we propose the addition of PGP9.5 immunostaining to the clinical and histological assessment of parathyroid malignancy for increased sensitivity without loss of specificity. Parafibromin immunohistochemistry is now routinely performed for World Health Organization-classified parathyroid carcinomas as well as atypical tumors in many pathology laboratories. Tumors that are clearly benign do not warrant immunohistochemistry. Tumors that are histopathologically malignant should be treated as carcinoma regardless of the immunohistochemistry profile, but immunohistochemistry is still valuable because it helps to triage genetic testing for HRPT2. Our suggested approach for the differential diagnosis of indeterminate or atypical parathyroid tumors is summarized in Fig.  3 . All histopathologically atypical parathyroid tumors should undergo parafibromin and PGP9.5 immunohistochemistry. Tumors that are parafibromin negative using the strict immunohistochemical criteria that we have outlined should be classified as low-grade parathyroid carcinomas and offered wide local excision, close clinical follow-up, and genetic testing for HRPT2 mutation. In these cases, positivity for PGP9.5 adds confidence to negative parafibromin staining but does not increase sensitivity. To date, we have not observed any cases that were negative for both proteins. Atypical tumors that are positive for both parafibromin and PGP9.5 should be classified as having a high risk of malignancy. Such tumors may harbor an HRPT2 mutation that does not result in complete loss of parafibromin staining as observed in this study. Alternatively, they may be among the approximately 30% of parathyroid malignant tumors that develop independent of loss of parafibromin. We believe that it is reasonable to offer patients with these tumors wide local excision, close clinical follow-up, and genetic testing for HRPT2 mutations. Atypical tumors that are parafibromin positive and PGP9.5 negative should be classified as (atypical) adenomas with low risk of malignancy and offered clinical follow-up without further intervention on the basis of the very low risk of aggressive behavior (40) .
In conclusion, this study shows that the incorporation of PGP9.5 immunostaining into the diagnostic criteria for parathyroid malignancy will increase the sensitivity of detection of malignancy or risk of malignancy based on the presence of an HRPT2 mutation in both parafibromin-dependent and -independent tumors without compromising specificity.
